Muscle Elastography in Spastic Cerebral Palsy
Use of Elastography to Quantify Change in Upper Extremity Muscle Spasticity Following Botox Injection in Children With Spastic Cerebral Palsy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10021
- Hospital for Special Surgery
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with unilateral spastic cerebral palsy with presence of dynamic muscle spasticity in the elbow and/or wrist flexors, who will be able to provide consent.
- Consent may be obtained from a parent or legal guardian, as applicable.
Exclusion Criteria:
- Prior surgical procedure in the affected upper extremity
- Unrelated orthopedic injury to the affected upper extremity
- Current oral or intrathecal antispasticity therapy
- Prior Botulinum toxin type A injection in preceding 6 months
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Muscle Elasticity
Time Frame: From immediate pre-injection to 1 month post-injection.
|
Change in muscle elasticity (in kilopascal )
|
From immediate pre-injection to 1 month post-injection.
|
|
Muscle Elasticity
Time Frame: From immediate pre-injection to 1 month post-injection.
|
Change in muscle elasticity (in m/s)
|
From immediate pre-injection to 1 month post-injection.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Functional measures
Time Frame: immediately pre- and immediately post-injection, and at 1 month, 3 months and 6 months post-injection.
|
Functional measures (MAS)
|
immediately pre- and immediately post-injection, and at 1 month, 3 months and 6 months post-injection.
|
|
Functional measures
Time Frame: immediately pre- and immediately post-injection, and at 1 month, 3 months and 6 months post-injection.
|
Functional measures (PROM)
|
immediately pre- and immediately post-injection, and at 1 month, 3 months and 6 months post-injection.
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Brain Damage, Chronic
- Musculoskeletal Diseases
- Muscular Diseases
- Neuromuscular Manifestations
- Muscle Hypertonia
- Cerebral Palsy
- Muscle Spasticity
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Cholinergic Agents
- Membrane Transport Modulators
- Acetylcholine Release Inhibitors
- Neuromuscular Agents
- Botulinum Toxins
- Botulinum Toxins, Type A
- abobotulinumtoxinA
Other Study ID Numbers
Other Study ID Numbers
- 2016-628
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Unilateral Spastic Cerebral Palsy
-
NCT07482631Not yet recruitingUnilateral Spastic Cerebral Palsy
-
NCT03888443CompletedUnilateral Spastic Cerebral Palsy
-
NCT07573865Not yet recruitingCerebral Palsy (CP) | Unilateral Cerebral Palsy | Spastic Cerebral Palsy (sCP)
-
NCT07247331CompletedCerebral Palsy | Hemiplegic Cerebral Palsy | Spastic Diplegia Cerebral Palsy
-
NCT07474818Not yet recruitingSpastic Diplegia Cerebral Palsy
-
NCT07488429RecruitingCerebral Palsy (CP) | Cerebral Palsy, Spastic, Diplegic | Diplegic Cerebral Palsy With Spasticity | Transcranial Magnetic Stimilation
-
NCT07347795Active, not recruitingCerebral Palsy Spastic Hemiplegic
-
NCT07233031CompletedCerebral Palsy Spastic Hemiplegic
-
NCT04231227CompletedCerebral Palsy | Cerebral Palsy, Spastic | Cerebral Palsy Spastic Diplegia | Cerebral Palsy Quadriplegic | Cerebral Palsy, Monoplegic
-
NCT07421505Not yet recruitingSpastic Diplegia Cerebral Palsy | Spastic Hemiplegia
Clinical Trials on Botulinum toxin type A
-
NCT00575016Terminated
-
NCT00461292Completed
-
NCT00311376Completed
-
NCT00752258Completed
-
NCT00989768CompletedWrinkles in Frontal Area
-
NCT04443244CompletedBenign Masseteric Hypertrophy
-
NCT00752050CompletedGlabellar Rhytides | Frown Lines Between the Eyebrows
-
NCT03905304CompletedCervical Dystonia
-
NCT07622004Completed